## Jorge GonzÃ;lez-Bacerio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5820258/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modeling and experimental validation of covalent immobilization of <i>Trametes maxima</i> laccase on glyoxyl and MANAâ€Sepharose CL 4B supports, for the use in bioconversion of residual colorants. Biotechnology and Applied Biochemistry, 2022, 69, 479-491.	3.1	4
2	Bacterial metalo-aminopeptidases as targets in human infectious diseases. Current Drug Targets, 2022, 23, .	2.1	1
3	Optimization of theoretical maximal quantity of cells to immobilize on solid supports in the rational design of immobilized derivatives strategy. World Journal of Microbiology and Biotechnology, 2021, 37, 9.	3.6	1
4	Modeling and Experimental Validation of Algorithms for Maximum Quantity of Protein to be Immobilized on Solid Supports by Electrostatic Adsorption in the Strategy of Rational Design of Immobilized Derivatives. Protein Journal, 2021, 40, 576-588.	1.6	3
5	Expression in Escherichia coli, purification and kinetic characterization of LAPLm, a Leishmania major M17-aminopeptidase. Protein Expression and Purification, 2021, 183, 105877.	1.3	3
6	Using microbial metalo-aminopeptidases as targets in human infectious diseases. Microbial Cell, 2021, 8, 239-246.	3.2	3
7	KBE009: A Bestatin-Like Inhibitor of the Trypanosoma cruzi Acidic M17 Aminopeptidase with In Vitro Anti-Trypanosomal Activity. Life, 2021, 11, 1037.	2.4	1
8	Overexpression of Plasmodium falciparum M1 Aminopeptidase Promotes an Increase in Intracellular Proteolysis and Modifies the Asexual Erythrocytic Cycle Development. Pathogens, 2021, 10, 1452.	2.8	0
9	Development of a High-Throughput Screening Assay to Identify Inhibitors of the Major M17-Leucyl Aminopeptidase from Trypanosoma cruzi Using RapidFire Mass Spectrometry. SLAS Discovery, 2020, 25, 1064-1071.	2.7	10
10	Screening and Immobilization of Interfacial Esterases from Marine Invertebrates as Promising Biocatalyst Derivatives. Applied Biochemistry and Biotechnology, 2019, 189, 903-918.	2.9	2
11	High-Level Expression in Escherichia coli, Purification and Kinetic Characterization of LAPTc, a Trypanosoma cruzi M17-Aminopeptidase. Protein Journal, 2019, 38, 167-180.	1.6	10
12	Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics. European Journal of Medicinal Chemistry, 2019, 163, 481-499.	5.5	29
13	Rational Design Strategy as a Novel Immobilization Methodology Applied to Lipases and Phospholipases. Methods in Molecular Biology, 2018, 1835, 243-283.	0.9	8
14	Rational design and synthesis of affinity matrices based on proteases immobilized onto cellulose membranes. Preparative Biochemistry and Biotechnology, 2017, 47, 745-753.	1.9	4
15	KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library. Bioorganic and Medicinal Chemistry, 2017, 25, 4628-4636.	3.0	15
16	Improved purification and enzymatic properties of a mixture of Sticholysin I and II: Isotoxins with hemolytic and phospholipase A2 activities from the sea anemone Stichodactyla helianthus. Protein Expression and Purification, 2014, 95, 57-66.	1.3	7
17	High-level expression in Escherichia coli, purification and kinetic characterization of Plasmodium falciparum M1-aminopeptidase. Protein Expression and Purification, 2014, 104, 103-114.	1.3	5
18	Combinatorial Multicomponent Access to Naturalâ€Productsâ€Inspired Peptidomimetics: Discovery of Selective Inhibitors of Microbial Metalloâ€aminopeptidases. ChemMedChem, 2014, 9, 2351-2359.	3.2	19

#	Article	IF	CITATIONS
19	Plasmodium falciparum M1-Aminopeptidase: A Promising Target for the Development of Antimalarials. Current Drug Targets, 2014, 15, 1144-1165.	2.1	16